22.03.2013 Views

COMMENTARY - US Pharmacopeial Convention

COMMENTARY - US Pharmacopeial Convention

COMMENTARY - US Pharmacopeial Convention

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

<strong>COMMENTARY</strong>– <strong>US</strong>P 32-NF 27 Second Supplement<br />

is recommended that this test be performed on the Active Pharmaceutical Ingredient<br />

(API) rather than drug product.<br />

Comment Summary #6: The commenters indicated that the column specified in the<br />

procedure should be removed from the General Chapter because the column is no<br />

longer manufactured.<br />

Response: Comment not incorporated because the appropriate column is commercially<br />

available.<br />

Comment Summary #7: The commenters indicated that the quality of the heparinases<br />

is one of the major uncontrolled variables and therefore suggested that <strong>US</strong>P could<br />

either qualify such materials or provide them as Reference Standards.<br />

Response: Comment not incorporated because the quality of heparinases is controlled<br />

by the system suitability requirements described in the procedure.<br />

Comment Summary #8: The commenter suggested including High Performance Liquid<br />

Chromatography (HPLC) system parameters in order to ensure reproducible results<br />

between laboratories.<br />

Response: Comment not incorporated because the <strong>US</strong>P Enoxaparin Sodium<br />

Reference Standard and the associated reference chromatogram provide the<br />

appropriate controls for reproducible results between laboratories.<br />

Comment Summary #9: The commenter indicated that the concentration of acetic acid<br />

used in the method is not specified.<br />

Response: Comment incorporated to specify glacial acetic acid.<br />

Comment Summary #10: The commenter indicated that the storage conditions for<br />

material after depolymerization are not specified.<br />

Response: Comment incorporated to specify storage conditions.<br />

Comment Summary #11: The commenter indicated that the volume specified for<br />

exposure to sodium borohydride is difficult to transfer to an HPLC vial because foaming<br />

occurs upon mixing; therefore, the sample requires centrifuging before transferring to<br />

the HPLC vial.<br />

Response: Comment not incorporated because gentle mixing minimizes foaming.<br />

Comment Summary #12: The commenter suggested including requirements for<br />

expiration dates and storage conditions for mobile phases, buffers, and enzyme<br />

cocktail.<br />

Response: Comment not incorporated because expiration dates and storage conditions<br />

are manufacturing documentation and labeling requirements for regulated products.<br />

General Chapter/Section(s): Residual Solvents/Other Analytical Procedures<br />

Expert Committee(s): General Chapters<br />

No. of Commenters: 1<br />

Comment Summary #1: The commenter indicated retaining Methods I, IV, V, and VI<br />

because the Methods are used to quantitate residual solvents in approved marketed<br />

products.<br />

Response: Comment not incorporated because no supporting data was provided,<br />

indicating that these methods provide the necessary specificity and sensitivity for<br />

quantitation of the solvents listed in the current version of General Chapter <br />

Residual Solvents.<br />

- 4 -

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!